Praxis precision medicines adds global business expertise to board of directors with appointment of jill desimone

Boston, may 23, 2022 (globe newswire) -- praxis precision medicines, inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today announced the appointment of jill desimone to its board of directors.
PRAX Ratings Summary
PRAX Quant Ranking